Background:
EpCAM and VEGFR2 play an important role in angiogenesis and
tumorigenesis. It is currently of paramount importance to produce new
drugs that can inhibit the angiogenesis and proliferation of tumor
cells. Nanobodies are potential drug candidates for cancer therapy due
to their unique properties.
Objective:
This study aimed to investigate the combined inhibitory effect of
anti-EpCAM and anti-VEGFR2 nanobodies in cancer cell lines.
Methods:
Inhibitory activity of anti-EpCAM and anti-VEGFR2 nanobodies on
MDA-MB231, MCF7, and HUVEC cells was investigated using both in vitro
(MTT, migration, and tube formation assays) and in vivo assays.
Results:
Results showed that the combination of anti-EpCAM and anti-VEGFR2
nanobodies efficiently inhibited proliferation, migration, and tube
formation of MDA-MB-231 cells compared to each individual nanobodies (p
< 0.05). In addition, the combination of anti-EpCAM and anti-VEGFR2
nanobodies efficiently inhibited tumor growth and volume of Nude mice
bearing MDA-MB-231 cells (p < 0.05).
Conclusion:
Taken together, the results indicate the potential of combination therapy as an efficient approach to cancer therapy.